These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 33328453)

  • 21. An overview of human proteins and genes involved in SARS-CoV-2 infection.
    Jahanafrooz Z; Chen Z; Bao J; Li H; Lipworth L; Guo X
    Gene; 2022 Jan; 808():145963. PubMed ID: 34530086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common Genetic Variation in Humans Impacts In Vitro Susceptibility to SARS-CoV-2 Infection.
    Dobrindt K; Hoagland DA; Seah C; Kassim B; O'Shea CP; Murphy A; Iskhakova M; Fernando MB; Powell SK; Deans PJM; Javidfar B; Peter C; Møller R; Uhl SA; Garcia MF; Kimura M; Iwasawa K; Crary JF; Kotton DN; Takebe T; Huckins LM; tenOever BR; Akbarian S; Brennand KJ
    Stem Cell Reports; 2021 Mar; 16(3):505-518. PubMed ID: 33636110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide bioinformatic analyses predict key host and viral factors in SARS-CoV-2 pathogenesis.
    Ferrarini MG; Lal A; Rebollo R; Gruber AJ; Guarracino A; Gonzalez IM; Floyd T; de Oliveira DS; Shanklin J; Beausoleil E; Pusa T; Pickett BE; Aguiar-Pulido V
    Commun Biol; 2021 May; 4(1):590. PubMed ID: 34002013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated temperature inhibits SARS-CoV-2 replication in respiratory epithelium independently of IFN-mediated innate immune defenses.
    Herder V; Dee K; Wojtus JK; Epifano I; Goldfarb D; Rozario C; Gu Q; Da Silva Filipe A; Nomikou K; Nichols J; Jarrett RF; Stevenson A; McFarlane S; Stewart ME; Szemiel AM; Pinto RM; Masdefiol Garriga A; Davis C; Allan J; Graham SV; Murcia PR; Boutell C
    PLoS Biol; 2021 Dec; 19(12):e3001065. PubMed ID: 34932557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets.
    Li Y; Duche A; Sayer MR; Roosan D; Khalafalla FG; Ostrom RS; Totonchy J; Roosan MR
    BMC Genomics; 2021 Feb; 22(1):125. PubMed ID: 33602138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection.
    Klaassen K; Stankovic B; Zukic B; Kotur N; Gasic V; Pavlovic S; Stojiljkovic M
    Infect Genet Evol; 2020 Oct; 84():104498. PubMed ID: 32771700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.
    Hasankhani A; Bahrami A; Sheybani N; Aria B; Hemati B; Fatehi F; Ghaem Maghami Farahani H; Javanmard G; Rezaee M; Kastelic JP; Barkema HW
    Front Immunol; 2021; 12():789317. PubMed ID: 34975885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium.
    Kasela S; Ortega VE; Martorella M; Garudadri S; Nguyen J; Ampleford E; Pasanen A; Nerella S; Buschur KL; Barjaktarevic IZ; Barr RG; Bleecker ER; Bowler RP; Comellas AP; Cooper CB; Couper DJ; Criner GJ; Curtis JL; Han MK; Hansel NN; Hoffman EA; Kaner RJ; Krishnan JA; Martinez FJ; McDonald MN; Meyers DA; Paine R; Peters SP; Castro M; Denlinger LC; Erzurum SC; Fahy JV; Israel E; Jarjour NN; Levy BD; Li X; Moore WC; Wenzel SE; Zein J; ; ; Langelier C; Woodruff PG; Lappalainen T; Christenson SA
    Genome Med; 2021 Apr; 13(1):66. PubMed ID: 33883027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular host factors for SARS-CoV-2 infection.
    Baggen J; Vanstreels E; Jansen S; Daelemans D
    Nat Microbiol; 2021 Oct; 6(10):1219-1232. PubMed ID: 34471255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational Identification of Human Biological Processes and Protein Sequence Motifs Putatively Targeted by SARS-CoV-2 Proteins Using Protein-Protein Interaction Networks.
    Nadeau R; Shahryari Fard S; Scheer A; Hashimoto-Roth E; Nygard D; Abramchuk I; Chung YE; Bennett SAL; Lavallée-Adam M
    J Proteome Res; 2020 Nov; 19(11):4553-4566. PubMed ID: 33103435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
    Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
    Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic variation analyses indicate conserved SARS-CoV-2-host interaction and varied genetic adaptation in immune response factors in modern human evolution.
    Lee JW; Lee IH; Sato T; Kong SW; Iimura T
    Dev Growth Differ; 2021 Apr; 63(3):219-227. PubMed ID: 33595856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genome interaction of the virus and the host genes and non-coding RNAs in SARS-CoV-2 infection.
    Serpeloni JM; Lima Neto QA; Lucio LC; Ramão A; Carvalho de Oliveira J; Gradia DF; Malheiros D; Ferrasa A; Marchi R; Figueiredo DLA; Silva WA; Ribeiro EMSF; Cólus IMS; Cavalli LR
    Immunobiology; 2021 Sep; 226(5):152130. PubMed ID: 34425415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conserved Genomic Terminals of SARS-CoV-2 as Coevolving Functional Elements and Potential Therapeutic Targets.
    Chan AP; Choi Y; Schork NJ
    mSphere; 2020 Nov; 5(6):. PubMed ID: 33239366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.
    Cheng K; Martin-Sancho L; Pal LR; Pu Y; Riva L; Yin X; Sinha S; Nair NU; Chanda SK; Ruppin E
    Mol Syst Biol; 2021 Nov; 17(11):e10260. PubMed ID: 34709707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 biology and variants: anticipation of viral evolution and what needs to be done.
    Luo R; Delaunay-Moisan A; Timmis K; Danchin A
    Environ Microbiol; 2021 May; 23(5):2339-2363. PubMed ID: 33769683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19.
    Kumar A; Parashar R; Kumar S; Faiq MA; Kumari C; Kulandhasamy M; Narayan RK; Jha RK; Singh HN; Prasoon P; Pandey SN; Kant K
    J Med Virol; 2022 Apr; 94(4):1300-1314. PubMed ID: 34811761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overlapping host pathways between SARS-CoV-2 and its potential copathogens: An in silico analysis.
    Vavougios GD
    Infect Genet Evol; 2020 Dec; 86():104602. PubMed ID: 33132111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.
    Policard M; Jain S; Rego S; Dakshanamurthy S
    Virus Res; 2021 Aug; 301():198464. PubMed ID: 34058265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.